Lucid Genomics: 1.3 million euros for groundbreaking DNA analyzes

Veröffentlicht:

Von: NAG Redaktion

Lucid Genomics erhält 1,3 Millionen Euro Pre-Seed-Finanzierung für die Entwicklung einer KI-basierten Digital-HealthTech-Plattform zur umfassenden DNA-Analyse. Das Berliner Start-up zielt darauf ab, genetisch bedingte Krankheiten präziser zu identifizieren und nutzt innovative Technologien, um bislang ungenutzte Bereiche des Genoms auszuwerten. Erfahren Sie mehr über die bahnbrechenden Ansätze in der Genomforschung und deren potenzielle Auswirkungen auf die Medizin.
Lucid Genomics receives 1.3 million euros in pre-seed financing for the development of a AI-based digital-health tech platform for comprehensive DNA analysis. The Berlin start-up aims to identify genetically determined diseases more precisely and uses innovative technologies to evaluate previously unused areas of the genome. Learn more about the groundbreaking approaches in genome research and their potential effects on medicine. (Symbolbild/MB)

Lucid Genomics: Pioneering work in DNA analysis through innovative financing

The aspiring Berlin start-up Lucid Genomics has successfully secured pre-seed finding of 1.3 million euros in an exciting development in the field of health and biotechnology. This fresh capital promises not only an improvement in the diagnosis of genetic diseases, but also significant progress in drug development.

The company, a spin-off of the renowned Max Planck Institute for Molecular Genetics and the Charité-University Medical Center Berlin, was launched by Uirá Souto Melo (CEO) and Hossein Morezadeh (CTO). There are significant scientific minds behind the foundation such as Prof. Dr. Stefan Mundlos and Prof. Dr. Martin Vingron. This strong foundation enables Lucid Genomics to develop a AI-based digital health tech platform that aims to enable comprehensive DNA analyzes.

The Lucid Genomics project is of outstanding importance, since it overcomes previous analysis approaches, which are often limited to small parts of the human genome. A large part of the genetic material, which is known as the "dark genome" and includes non-coding areas, often remains undetected. The innovative technology of Lucid Genomics, which is based on machine learning, has the potential to capture and decrypt great genetic variants that could be decisive for health.

By its unique algorithms, which were developed to identify complex patterns in human DNA, Lucid Genomics could enable important progress in precision medicine. "Our vision is to offer a digital solution that is able to process all DNA sequencing data," says Hossein Morezadeh. Such a project could revolutionize the early cancer recognition and change the development of new therapies.

The financing round was led by Caesar Ventures and other investors such as B.I.F. Partners and the MPF Accelerator Program supported. A significant part of the capital recording is also used to further develop the technical platform in order to identify genetic mutations more efficiently. In the first phase, the founders plan to concentrate on rare genetic diseases before expanding their technology to cancer diagnostics and other medical areas.

Another advantage of the company is the close cooperation with programs such as K.I.E.Z. (Artificial intelligence entrepreneurship center), which targeted the promotion of scientific foundations in the field of artificial intelligence. Since its foundation, K.I.E.Z. Supported a variety of AI start-ups in Berlin and contributes to the development of innovative solutions in biotechnology.

Secured financing not only represents financial support, but is also a signal for the trust in the transformative power of technology in the health sector. The developments of Lucid Genomics could have a far -reaching influence that goes far beyond diagnostics and ultimately can improve the lives of many people.